新闻
IBIO
0.7300
+0.27%
0.0020
iBio 为价值 350 万美元的股票定价,认股权证公开发售
iBio 为价值 350 万美元的股票定价,认股权证公开发售
MT Newswires · 2022/12/07 04:45
iBio 首席执行官 Thomas Isett 卸任
iBio 首席执行官 Thomas Isett 卸任
MT Newswires · 2022/12/02 16:56
iBio 出售合同开发业务以专注于药物发现,削减 60% 的劳动力;首席执行官伊塞特离职
iBio 出售合同开发业务以专注于药物发现,削减 60% 的劳动力;首席执行官伊塞特离职
MT Newswires · 2022/11/03 12:50
康托尔菲茨杰拉德降级后 iBio 股价下跌
康托尔菲茨杰拉德降级后 iBio 股价下跌
MT Newswires · 2022/10/07 13:14
--Cantor Fitzgerald 将 iBio 评级从增持下调至中性,将目标价从 2.50 美元下调至 0.17 美元
--Cantor Fitzgerald 将 iBio 评级从增持下调至中性,将目标价从 2.50 美元下调至 0.17 美元
MT Newswires · 2022/10/07 05:39
iBio 表示存在“重大疑问”它可以“继续经营”;数小时后股价暴跌
iBio 表示存在“重大疑问”它可以“继续经营”;数小时后股价暴跌
MT Newswires · 2022/09/27 16:46
iBio 股价在完成收购 RubrYc Therapeutics 资产后上涨
iBio 股价在完成收购 RubrYc Therapeutics 资产后上涨
MT Newswires · 2022/09/21 10:41
美股抗疫概念股普跌
美股抗疫概念股普跌
格隆汇 · 2021/12/27 15:11
美股开盘 | 三大指数涨跌不一,360数科(QFIN.US)涨超9%
美股开盘 | 三大指数涨跌不一,360数科(QFIN.US)涨超9%
智通财经 · 2021/07/09 13:30
美股前瞻 | 三大股指期货齐涨,热门中概股盘前上扬
美股前瞻 | 三大股指期货齐涨,热门中概股盘前上扬
智通财经 · 2021/07/09 12:00
更多
微牛提供丰富的实时IBIO股票新闻,让你可以通过多个平台了解IBIO股票行情最新动态,这些免费的IBIO新闻可以帮助你做出明智投资。
IBIO 简况
iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.